Library

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

1 January 2016. doid: 10.1016/j.trci.2015.12.003

Baakman AC, 't Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ

View publication

Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors, with improved effectiveness.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact